Bicycle Therapeutics PLC

자세한 내용은 Bicycle Therapeutics PLC 회사

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

회사 정보

종목 코드 BCYC

회사 이름Bicycle Therapeutics PLC

상장일May 23, 2019

CEODr. Kevin Lee, Ph.D.

직원 수305

유형Depository Receipt

회계 연도 종료May 23

주소Blocks A & B, Portway Building

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United Kingdom

우편 번호CB21 6GS

전화11441223261503

웹사이트https://www.bicycletherapeutics.com/

종목 코드 BCYC

상장일May 23, 2019

CEODr. Kevin Lee, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Mr. Eric Westin, M.D.

Chief Medical Officer

--

Dr. Alessandro Riva, M.D.

Non-Executive Independent Director

--

Mr. Stephen Sands

Non-Executive Independent Director

--

Dr. Jose Carlos Gutierrez-Ramos, Ph.D.

Non-Executive Independent Director

--

Mr. Felix J. Baker, Ph.D.

Non-Executive Independent Chairman of the Board

--

Mr. Michael Hannay

Chief Product and Supply Chain Officer

--

이름

이름/직위

직위

주식 보유

변동

Dr. Kevin Lee, Ph.D.

Chief Executive Officer, Executive Director

275.59K

-23.43%

Dr. Michael Skynner, Ph.D.

Chief Technology Officer

72.92K

+73.03%

Mr. Alistair Milnes

Chief Operating Officer

25.33K

-65.69%

Ms. Janice Bourque

Non-Executive Independent Director

18.31K

+49.49%

Mr. Eric Westin, M.D.

Chief Medical Officer

--

Dr. Alessandro Riva, M.D.

Non-Executive Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Mon, Jul 14

주주

주주 유형

주주

비율

Baker Bros. Advisors LP

22.79%

Point72 Asset Management, L.P.

7.73%

Forbion Capital Partners

7.23%

Armistice Capital LLC

5.59%

Westfield Capital Management Company, L.P.

5.56%

Other

51.09%

주주

비율

Baker Bros. Advisors LP

22.79%

Point72 Asset Management, L.P.

7.73%

Forbion Capital Partners

7.23%

Armistice Capital LLC

5.59%

Westfield Capital Management Company, L.P.

5.56%

Other

51.09%

주주 유형

주주

비율

Hedge Fund

47.52%

Investment Advisor

17.21%

Investment Advisor/Hedge Fund

15.44%

Venture Capital

9.66%

Research Firm

3.69%

Individual Investor

1.60%

Pension Fund

0.20%

Family Office

0.06%

Other

4.61%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

261

45.57M

95.34%

-15.98M

2025Q1

263

46.04M

96.46%

-15.64M

2024Q4

263

44.84M

86.26%

-16.34M

2024Q3

260

44.49M

67.19%

-14.65M

2024Q2

252

44.12M

95.17%

-7.15M

2024Q1

268

34.84M

83.52%

-13.88M

2023Q4

272

34.95M

93.64%

-12.28M

2023Q3

272

41.70M

105.20%

-747.70K

2023Q2

255

34.13M

112.16%

-8.01M

2023Q1

245

32.53M

108.64%

-4.04M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Baker Bros. Advisors LP

10.89M

22.79%

-8.80K

-0.08%

Mar 31, 2025

Point72 Asset Management, L.P.

3.69M

7.73%

-862.83K

-18.94%

Mar 31, 2025

Forbion Capital Partners

3.45M

7.23%

--

Mar 31, 2025

Armistice Capital LLC

2.67M

5.59%

+476.00K

+21.68%

Mar 31, 2025

Westfield Capital Management Company, L.P.

2.66M

5.56%

+46.97K

+1.80%

Mar 31, 2025

Invus Public Equities Advisors, LLC

1.81M

3.8%

-26.65K

-1.45%

Mar 31, 2025

T. Rowe Price Associates, Inc.

1.54M

3.22%

-48.54K

-3.06%

Mar 31, 2025

Candriam Luxembourg S.A.

1.21M

2.53%

-20.80K

-1.69%

May 31, 2025

Long Focus Capital Management LLC

1.29M

2.71%

+750.66K

+138.22%

Mar 31, 2025

BNP Paribas Asset Management USA, Inc.

1.22M

2.55%

+64.04K

+5.54%

Mar 31, 2025

8.025USD

Bicycle Therapeutics PLC

8.025

개요

회사

금융